We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Boots OTC divestiture

This article was originally published in The Tan Sheet

18 Jul 2005

News

Executive Summary

Boots Group has provided a "memorandum of information" on its consumer unit, Boots Healthcare International, to parties who are "seriously interested" in purchasing the division, the firm said. The divestiture of the unit, which includes Clearasil skin care, Nurofen (ibuprofen) and Strepsils lozenges, is on track for completion by March 2006. Plans for the sale were announced in May (1"The Tan Sheet" May 30, 2005, p. 7)...